Saimaa Generics Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 3.37 M
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.75 Cr
- Revenue Growth -9.28%
- Profit Growth 11.42%
- Ebitda 10.12%
- Net Worth 29.63%
- Total Assets 6.65%
About Saimaa Generics
Saimaa Generics Private Limited (SGPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 28 February 2002 and has a history of 22 years and 11 months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.37 M.
The company has closed loans amounting to ₹1.75 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Naveen Khanna and Ritu Khanna serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230WB2002PTC094308
- Company No.
094308
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Feb 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Saimaa Generics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naveen Khanna  | Director | 28-Feb-2002 | Current |
| Ritu Khanna | Director | 28-Feb-2002 | Current |
Financial Performance of Saimaa Generics.
Saimaa Generics Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 9.28% decrease. The company also saw a substantial improvement in profitability, with a 11.42% increase in profit. The company's net worth Soared by an impressive increase of 29.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saimaa Generics?
In 2019, Saimaa Generics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹17.50 M
Charges Breakdown by Lending Institutions
- Union Bank Of India : 1.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jan 2007 | Union Bank Of India | ₹9.00 M | Satisfied |
| 10 Feb 2003 | Union Bank Of India | ₹8.50 M | Satisfied |
How Many Employees Work at Saimaa Generics?
Unlock and access historical data on people associated with Saimaa Generics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saimaa Generics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saimaa Generics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
